Clinical Trial Update: Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant cemiplimab versus placebo after surgery and radiation for high-risk cutaneous squamous cell carcinoma. The study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Cutaneous Squamous Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING